close

Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. It has a global partnership with Roche for developing novel CRACM inhibitors, an oral calcium released activated calcium modulator ion channel inhibitor program that is in the lead optimization stage for the treatment of autoimmune diseases. The company also retains rights in various indications and markets to its other drug candidates and programs, which include STA-9090, an Hsp90 inhibitor that is in Phase 1 development; elesclomol, an oxidative stress inducer for the treatment of cancer; and apilimod, an oral IL-12/23 inhibitor, which is in Phase 2 for rheumatoid arthritis. In addition, Synta Pharmaceuticals Corp. is developing STA-9584, a vascular disrupting agent that is in preclinical development. The company was incorporated in 2000 and is based in Lexington, Massachusetts.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	4.64
Volume	160355
Volume Avg	335662
52 Week High	6.27
52 Week Low	3.02
PE	N/A
PE (group average)	N/A
EPS Year	-1.00
EPS change Q/Q	-28.57%
EPS change Q/Q Yr ago	-12.5%
EPS change Q/Q next Q est	-8%
EPS change Y/Y	-1000%
REV change Q/Q	-72.5%
REV change Q/Q Yr ago	-72.5%
EPS next Q est	-0.25
EPS next Y est	-0.95
Divident Annual	0.00
Dividend Yield	0%